TUS-PHARMA(SZ:000590) Zheng Quan Zhi Xing·2025-08-08 16:23Core Viewpoint - The announcement indicates that the controlling shareholder of Qidi Pharmaceutical will undergo a change due to the judicial auction of shares held by its subsidiary, resulting in a significant shift in the company's ownership structure and governance [1][2]. Group 1: Overview of Judicial Auction - Qidi Pharmaceutical received a court ruling that mandates the transfer of 58,606,962 shares to Hunan Sailoxian Management Consulting Partnership, which represents 24.47% of the company's total share capital [1][2]. - The shares were successfully auctioned for a total price of 1,007,392,612.46 yuan [2]. Group 2: Details of Equity Change - Following the auction, Qidi Technology Service Co., Ltd. will no longer hold any shares in Qidi Pharmaceutical, reducing its holdings from 63,151,413 shares (26.37%) to 4,544,451 shares (1.90%) [1][4]. - Hunan Sailoxian's shareholding will increase from 0 shares to 58,606,962 shares, representing 24.47% of the total share capital [1][4]. Group 3: Impact on Company Control - The change in shareholding will lead to a shift in the control of the company, which will have significant implications for its equity structure and governance [2][5]. - The transaction does not affect the company's independence in terms of business, assets, finance, personnel, or institutions from the controlling shareholder and its other controlled enterprises [4][5]. Group 4: Subsequent Matters and Regulations - The transaction does not trigger a mandatory takeover bid but involves a change in the controlling shareholder and actual controller [5]. - The shares acquired through the judicial auction cannot be transferred for 18 months post-acquisition, as per regulatory requirements [5].